In response to a request at the hearing for additional information, the department provided the following response in a letter to the Committee. Below is the information requested for which Public Services and Procurement Canada is accountable. Note that additional information will be provided by the Public Health Agency of Canada (PHAC) under separate cover (refer to Appendix D).

Question 1—Remaining vaccines (rephrased to be less political than the actual questions asked)

Under Canada’s Advance Purchase Agreements, there are currently 90.8 million remaining doses to be delivered in 2023 and 2024. Please refer to [Table A] for further details.

Question 2—Advance purchase agreements

The Government of Canada has committed over $9 billion to procure vaccines and therapeutics and to provide international support. PHAC is responsible for managing this funding as the client department.

Canada’s Advance Purchase Agreements provide flexibility to procure the latest formulations and presentations of COVID-19 vaccines, such as those to protect against mutations or variants of concern, and vaccines developed for younger populations. Booster doses may be acquired under the 90.8 million doses to be delivered in 2023 and 2024.

Question 3—Financial details

Canada’s Advance Purchase Agreements include strict confidentiality terms whereby the terms and conditions of the agreements, including the financial details, and the information pertaining to the relationship between Canada and the suppliers, are considered confidential information between both parties.

Question 4—Breakdown by advance purchase agreement

PSPC cannot provide an answer that specifically aligns to the information provided in exhibit 9.3. of the OAG report as requested by the Committee, but please see [Table A] for detailed information on Canada’s Advance Purchase Agreements broken down by supplier.

Table A—COVID 19 Vaccine Advance Purchase Agreements Breakdown

Notes: 1.        Firm dose commitments reflects the total firm dose commitment including those added through amendments.

2.     As of February 15, 2023.

3.     As of February 15, 2023, outstanding doses to be delivered in 2023 and 2024. May include firm doses as well as options exercised. Note this is net of Medicago and Sanofi’s firm commitments (see notes 4 & 5).

4.     Medicago and Canada are formalizing an agreement to terminate the contract by mutual consent.

5.     Sanofi and Canada are formalizing an agreement to terminate the contract by mutual consent.

6.     “M” stands for “million”